Programmed death 1 receptor changes ex vivo in hiv-infected adults following initiation of highly active antiretroviral therapy

9Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This study investigates the short-term effects of highly active antiretroviral therapy (HAART) on programmed death 1 receptor (PD-1) expression and lymphocyte function. We compared lymphocytes from human immunodeficiency virus (HIV)-infected adults prior to the initiation of HAART with lymphocytes from the same subjects following 2 months of treatment. Short-term HAART resulted in a moderate increase in the expression of PD-1 on both CD4 + and CD8 + T cells; yet, there was still a significant reduction in viral load and recovery of CD4 + T cells. After 2 months of HAART, lymphocytes from the subjects had a reduction in lymphoproliferative responses to phytohemagglutinin (PHA) and an increased response to the Candida recall antigen and the HIV antigen p24 compared to pretreatment lymphocytes. PHA-stimulated peripheral blood mononuclear cells (PBMCs) from samples obtained 2 months after HAART produced higher levels of Th-1 cytokines (gamma interferon [IFN-±] and tumor necrosis factor alpha[TNF-α]) than the levels observed for samples taken before treatment was initiated. There were no significant changes in the proinflammatory cytokine interleukin-2 (IL-2) or Th-2 cytokines (IL-4, IL-5, and IL-10) in the corresponding samples. Ex vivo PD-1 blockade significantly augmented PHA-induced lymphoproliferation as well as the levels of Th-1 cytokines and to a lesser extent the levels of Th-2 cytokines in PBMC cultures. The ability to downregulate PD-1 expression may be important in enhancing immune recovery in HIV infection. Copyright © 2012, American Society for Microbiology.

Cite

CITATION STYLE

APA

Spitsin, S., Tustin, N. B., Riedel, E., Tustin, R., Murray, J. B., Peck, L. M., … Douglas, S. D. (2012). Programmed death 1 receptor changes ex vivo in hiv-infected adults following initiation of highly active antiretroviral therapy. Clinical and Vaccine Immunology, 19(5), 752–756. https://doi.org/10.1128/CVI.00093-12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free